| P2093 | author name string | Ingvild Birschmann | |
| | Albrecht Gröner | |
| | Dietmar Fries | |
| | Cristina Solomon | |
| | Wolfgang Korte | |
| | Christine Joch | |
| | Inna Pendrak | |
| P2860 | cites work | International registry on factor XIII deficiency: a basis formed mostly on European data | Q31114612 |
| | Factor XIII deficiency | Q33785637 |
| | Prophylaxis in rare coagulation disorders -- factor XIII deficiency | Q36449902 |
| | Pharmacovigilance as a tool for safety and monitoring: a review of general issues and the specific challenges with end-stage renal failure patients. | Q36796470 |
| | New developments in the management of congenital Factor XIII deficiency | Q36906072 |
| | Prophylactic therapy with Fibrogammin P is associated with a decreased incidence of bleeding episodes: a retrospective study | Q37657623 |
| | The effect of plasma transfusion on morbidity and mortality: a systematic review and meta-analysis | Q37719659 |
| | Evaluation and management of acute menorrhagia in women with and without underlying bleeding disorders: consensus from an international expert panel | Q37883661 |
| | Novel aspects of factor XIII deficiency. | Q37898982 |
| | Factor XIII: a coagulation factor with multiple plasmatic and cellular functions | Q37899674 |
| | Biology of Factor XIII and clinical manifestations of Factor XIII deficiency | Q38038687 |
| | Cryoprecipitate: an outmoded treatment? | Q38044961 |
| | Factor XIII deficiency management: a review of the literature. | Q38176743 |
| | Efficacy and safety of prophylactic treatment with plasma-derived factor XIII concentrate (human) in patients with congenital factor XIII deficiency | Q42182012 |
| | Viral safety of human plasma-derived medicinal products: impact of regulation requirements | Q42253751 |
| | Corifact™/Fibrogammin® P in the prophylactic treatment of hereditary factor XIII deficiency: results of a prospective, multicenter, open-label study | Q42688987 |
| | Factor XIII replacement in stem-cell transplant recipients with severe hemorrhagic cystitis: a report of four cases | Q44221101 |
| | PCR detection of a low viral load in a prothrombin complex concentrate that transmitted hepatitis B virus | Q45769067 |
| | Management of acute myocardial infarction in a patient with factor XIII deficiency using prophylactic factor replacement therapy | Q45872227 |
| | Rare Bleeding Disorder Registry: deficiencies of factors II, V, VII, X, XIII, fibrinogen and dysfibrinogenemias | Q45873378 |
| | Acquired factor XIII deficiency: a therapeutic challenge. | Q51277928 |
| | Factor XIII substitution in surgical cancer patients at high risk for intraoperative bleeding. | Q51839300 |
| | Lack of clinical efficacy of additional factor XIII treatment in patients with steroid refractory colitis. The Factor XIII Study Group. | Q53922657 |
| | Guidelines for the use of fresh-frozen plasma, cryoprecipitate and cryosupernatant | Q56675460 |
| | Pharmacokinetics and tolerability of factor XIII concentrates prepared from human placenta or plasma: a crossover randomised study | Q70960395 |
| | Factor XIII substitution in ulcerative colitis | Q72540502 |
| | Assessment of menstrual blood loss using a pictorial chart: a validation study | Q73599964 |
| | Factor XIII prevents development of myocardial edema in children undergoing surgery for congenital heart disease | Q74225861 |
| | Factor XIII replacement in stem cell transplant (SCT) recipients with severe graft-versus-host disease of the bowel: report of an initial experience | Q77090337 |
| | The effect of factor XIII on bleeding in coronary surgery | Q77784380 |
| | Coagulation factor XIII reduces postoperative bleeding after coronary surgery with extracorporeal circulation | Q82584951 |
| | Factor XIII deficiency | Q83181285 |
| | Successful long-term replacement therapy with FXIII concentrate (Fibrogammin(®) P) for severe congenital factor XIII deficiency: a prospective multicentre study | Q83826080 |
| | Transfusion-associated circulatory overload after plasma transfusion | Q84564297 |
| | Clinical significance of blood coagulation factor XIII activity in adult Henoch-Schönlein purpura | Q87343081 |
| P433 | issue | 5 | |
| P1104 | number of pages | 9 | |
| P304 | page(s) | 365-373 | |
| P577 | publication date | 2016-08-03 | |
| P1433 | published in | Transfusion Medicine and Hemotherapy | Q15758504 |
| P1476 | title | Safety of Factor XIII Concentrate: Analysis of More than 20 Years of Pharmacovigilance Data | |
| P478 | volume | 43 | |